To amend title IV of the Public Health Service Act to prohibit sale or transactions relating to human fetal tissue.
Analysis under review: This bill has generated analysis that may be too generic or incomplete. Clause-level evidence remains available below.
Summary
What This Bill Does
The bill expands the definition of "valuable consideration" in existing federal law prohibiting human fetal tissue sales to include indirect financial benefits (waived fees, forgiven debts, reduced charges), non-monetary. It relies on definition changes. The main policy areas are Healthcare, Science & Space, Transportation, and Education.
Who Benefits and How
The available clause analysis does not identify a specific beneficiary group.
Who Bears the Burden and How
Tissue processing and storage laboratories could lose revenue opportunities, Medical research institutions using human fetal tissue would take on compliance duties, and Universities conducting fetal tissue research would take on compliance duties.
Key Provisions
- Expands the definition of "valuable consideration" in existing federal law prohibiting human fetal tissue sales to include indirect financial benefits (waived fees, forgiven debts, reduced charges), non-monetary...
Evidence Chain:
This summary is generated from the full bill text using AI analysis. Expand "Detailed Analysis" below for identified beneficiaries/burden bearers with clause-level evidence links.
At a Glance
What This Bill Does
The bill expands the definition of "valuable consideration" in existing federal law prohibiting human fetal tissue sales to include indirect financial benefits (waived fees, forgiven debts, reduced charges), non-monetary.
Key Policy Areas
Healthcare, Science & Space, Transportation, Education
Primary Purpose
The bill expands the definition of "valuable consideration" in existing federal law prohibiting human fetal tissue sales to include indirect financial benefits (waived fees, forgiven debts, reduced charges), non-monetary.
Policy Domains
Section 2 - Amendment to Public Health Service Act
Identified Costs
- Tissue processing and storage laboratories
- Medical research institutions using human fetal tissue
- Universities conducting fetal tissue research
- Transportation companies handling medical specimens
- Abortion providers and clinics
Sponsors
Legislative Progress
IntroducedMr. Scott Franklin of Florida (for himself, Mr. Weber of …
Stakeholder Effects
cui bono?How this legislation distributes effects. Mention counts reflect frequency, not effect magnitude.
Medical research institutions using human fetal tissue
Tissue processing and storage laboratories
Transportation companies handling medical specimens
Bill Structure & Actor Mappings
Who is "The Secretary" in each section?
- "the_secretary"
- → Secretary of Health and Human Services
Key Definitions
Terms defined in this bill
Expanded to include: (A) any payment made or debt incurred; (B) any gift, honorarium, or recognition of value bestowed; (C) any price, charge, or fee which is waived, forgiven, reduced, or indefinitely delayed; (D) any loan or debt which is canceled or otherwise forgiven; (E) the transfer of any item from one person to another or provision of any service or granting of any opportunity for which a charge is customarily made, without charge or for a reduced charge; and (F) any payments associated with the transportation, implantation, processing, preservation, quality control, or storage of human fetal tissue
We use a combination of our own taxonomy and classification in addition to large language models to assess meaning and potential beneficiaries. High confidence means strong textual evidence. Always verify with the original bill text.
Learn more about our methodology